Breaking News, Collaborations & Alliances

Evotec Earns $75M Milestone Under BMS Alliance

Relates to building a molecular glue-based pipeline.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Evotec SE announced further progress of the company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline, triggering a $75 million performance-based and program-based milestone payment to Evotec.   Initiated in 2018, the partnership combines Evotec’s high-performance multi-omics screening and analytics capabilities with Bristol Myers Squibb’s library of cereblon E3 ligase modulators (CELMoDs). Expanded in 2022, the partnership continues to iden...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters